RT Journal Article
SR Electronic
T1 Tumor genomic subtypes orthogonal to mutation burden predict the efficacy of immune checkpoint therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.03.21264330
DO 10.1101/2021.10.03.21264330
A1 Shiro Takamatsu
A1 Junzo Hamanishi
A1 J.B. Brown
A1 Ken Yamaguchi
A1 Koji Yamanoi
A1 Kosuke Murakami
A1 Osamu Gotoh
A1 Seiichi Mori
A1 Masaki Mandai
A1 Noriomi Matsumura
YR 2021
UL http://medrxiv.org/content/early/2021/10/04/2021.10.03.21264330.abstract
AB Background In cancer therapy, precise tumor-agnostic biomarkers that predict response to immune checkpoint inhibitors (ICIs) are needed. To explain treatment response differences among tumor types, the application of mutational signatures, patterns of genomic alterations that reflect differences in distinct underlying carcinogenic processes, holds promise but has not been extensively integrated into prediction methodologies.Methods Based on mutational signature analysis, we developed a stratification for all solid tumors in The Cancer Genome Atlas (TCGA). Then, we developed the Tumor Genomic Subtype Analyzer (TGSA) to classify tumors submitted to whole-exome sequencing. Using existing data from 938 pan-cancer ICI-treated cases with outcomes, we evaluated the subtype-response predictive performance.Results Systematic analysis on TCGA samples identified eight tumor genomic subtypes, which were characterized by features represented by smoking exposure, ultraviolet light exposure, APOBEC enzyme activity, POLE mutation, mismatch repair deficiency, homologous recombination deficiency, genomic stability, and aging. The former five subtypes were presumed to form an immune-responsive group acting as candidates for ICI therapy because of their high expression of immune-related genes and enrichment in cancer types with FDA approval for ICI monotherapy. In the validation cohort, the samples assigned by TGSA to the immune-reactive subtypes were significantly related to ICI response independent of cancer type and high TMB status.Conclusion Mutational signature-based tumor subtyping can serve as a tumor-agnostic biomarker for ICI response prediction. The results indicate that the mutational process underlying carcinogenesis affects tumor immunogenicity, and thus sensitivity to ICI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant No. 18H02945 and 18H02947.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Kyoto University Graduate School and Faculty of Medicine, Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesControlled access data used in this study were obtained from dbGaP, EGA, and NBDC with access permissions according to the respective required procedures. The processed data and analysis codes to reproduce the results of this work are available on the GitHub page (https://github.com/shirotak/pancancer_MutSig_ICI). Other codes for preprocessing or restricted-access data are available from the corresponding author upon reasonable request. https://github.com/shirotak/pancancer_MutSig_ICI ACCAdrenocortical carcinomaBLCABladder urothelial carcinomaBRCABreast invasive carcinomaCESCCervical squamous cell carcinoma and endocervical adenocarcinomaCHOLCholangiocarcinomaCRCColorectal adenocarcinomaESCAEsophageal carcinomaGBMGlioblastoma multiformeHNSCHead and neck squamous cell carcinomaKICHKidney chromophobeKIRCKidney renal clear cell carcinomaKIRPKidney renal papillary cell carcinomaLGGBrain lower grade gliomaLIHCLiver hepatocellular carcinomaLUADLung adenocarcinomaLUSCLung squamous cell carcinomaMESOMesotheliomaOVOvarian serous cystadenocarcinomaPAADPancreatic adenocarcinomaPCPGPheochromocytoma and paragangliomaPRADProstate adenocarcinomaSARCSarcomaSKCMSkin cutaneous melanomaSTADStomach adenocarcinomaTGCTTesticular germ cell tumorsTHCAThyroid carcinomaUCECUterine corpus endometrial carcinomaUCSUterine carcinosarcomaUVMUveal melanoma